These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20222815)

  • 1. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.
    Aquilante CL
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):359-72. PubMed ID: 20222815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
    Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
    Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing.
    Grant RW; Wexler DJ
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):339-43. PubMed ID: 20222813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.
    Swen JJ; Wessels JA; Krabben A; Assendelft WJ; Guchelaar HJ
    Pharmacogenomics; 2010 Nov; 11(11):1517-23. PubMed ID: 21121772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polymorphism of the sulfonylurea receptor gene in type 2 diabetes mellitus].
    Owecki M; Horst-Sikorska W; Kaczmarek M; Słomski R; Sowiński J
    Pol Arch Med Wewn; 2003 Feb; 109(2):143-8. PubMed ID: 12879777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.
    Manolopoulos VG; Ragia G; Tavridou A
    Pharmacogenomics; 2011 Aug; 12(8):1161-91. PubMed ID: 21843065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
    Suzuki K; Yanagawa T; Shibasaki T; Kaniwa N; Hasegawa R; Tohkin M
    Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCC8 polymorphisms are associated with triglyceride concentration in type 2 diabetics on sulfonylurea therapy.
    Nikolac N; Simundic AM; Saracevic A; Katalinic D
    Genet Test Mol Biomarkers; 2012 Aug; 16(8):924-30. PubMed ID: 22533711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
    Zhou K; Donnelly L; Burch L; Tavendale R; Doney AS; Leese G; Hattersley AT; McCarthy MI; Morris AD; Lang CC; Palmer CN; Pearson ER
    Clin Pharmacol Ther; 2010 Jan; 87(1):52-6. PubMed ID: 19794412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
    Sesti G; Laratta E; Cardellini M; Andreozzi F; Del Guerra S; Irace C; Gnasso A; Grupillo M; Lauro R; Hribal ML; Perticone F; Marchetti P
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2334-9. PubMed ID: 16595597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Tavridou A; Elens L; Van Schaik RH; Manolopoulos VG
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):60-3. PubMed ID: 24464600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care.
    Mitchell SL; Leon DAC; Chaugai S; Kawai VK; Levinson RT; Wei WQ; Stein CM
    Pharmacogenomics J; 2020 Dec; 20(6):831-839. PubMed ID: 32504053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfonylurea receptor gene 16-3 polymorphism - association with sulfonylurea or insulin treatment in type 2 diabetic subjects.
    Zychma MJ; Gumprecht J; Strojek K; Grzeszczak W; Moczulski D; Trautsolt W; Karasek D
    Med Sci Monit; 2002 Jul; 8(7):CR512-5. PubMed ID: 12118200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.
    Klen J; Dolžan V; Janež A
    Eur J Clin Pharmacol; 2014 Apr; 70(4):421-8. PubMed ID: 24442125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of type 2 diabetes mellitus and other specific types of diabetes; its role in treatment modalities.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(1):54-8. PubMed ID: 23014256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy.
    Muhammad SD; Khan H; Hussain M; Zeb TF; Kumar D; Rahi R; Asif M; Balooch AA
    Pak J Pharm Sci; 2020 Jul; 33(4(Supplementary)):1771-1777. PubMed ID: 33612460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes.
    Ren Q; Xiao D; Han X; Edwards SL; Wang H; Tang Y; Zhang S; Li X; Zhang X; Cai X; Liu Z; Paul SK; Ji L
    Diabetes Technol Ther; 2016 Sep; 18(9):586-93. PubMed ID: 27403931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics: the influence of genomic variation on drug response.
    Thomas FJ; McLeod HL; Watters JW
    Curr Top Med Chem; 2004; 4(13):1399-409. PubMed ID: 15379653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.
    Sato R; Watanabe H; Genma R; Takeuchi M; Maekawa M; Nakamura H
    Pharmacogenomics; 2010 Dec; 11(12):1743-50. PubMed ID: 21142918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.